Literature DB >> 16848694

The role of hypoxia inducible factor-1 in cell metabolism--a possible target in cancer therapy.

Rachida S Bel Aiba1, Elitsa Y Dimova, Agnes Görlach, Thomas Kietzmann.   

Abstract

In many cancer types, intratumoural hypoxia is linked to increased expression and activity of the transcription factor hypoxia-inducible factor (HIF-1alpha), which is associated with poor patient prognosis. This increased the interest in HIF-1alpha as a cancer drug target. Further, HIF-1alpha has also a central role in the adaptive cellular programme responding to hypoxia in normal tissues. Many of the HIF-1alpha-regulated genes encode enzymes of metabolic pathways. Therefore, studying the link and the feedback mechanisms between metabolism and HIF-1alpha is of major importance to find new and specific therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848694     DOI: 10.1517/14728222.10.4.583

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  4 in total

1.  Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism.

Authors:  Sajesh Parathath; Stephanie L Mick; Jonathan E Feig; Victor Joaquin; Lisa Grauer; David M Habiel; Max Gassmann; Lawrence B Gardner; Edward A Fisher
Journal:  Circ Res       Date:  2011-09-15       Impact factor: 17.367

2.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 3.  Application of Radiosensitizers in Cancer Radiotherapy.

Authors:  Liuyun Gong; Yujie Zhang; Chengcheng Liu; Mingzhen Zhang; Suxia Han
Journal:  Int J Nanomedicine       Date:  2021-02-12

Review 4.  RRx-001, A novel dinitroazetidine radiosensitizer.

Authors:  Bryan Oronsky; Jan Scicinski; Shoucheng Ning; Donna Peehl; Arnold Oronsky; Pedro Cabrales; Mark Bednarski; Susan Knox
Journal:  Invest New Drugs       Date:  2016-02-03       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.